We Are One Seven LLC Buys Shares of 1,171 Thermo Fisher Scientific Inc. (TMO)

We Are One Seven LLC bought a new position in Thermo Fisher Scientific Inc. (NYSE:TMO) during the 3rd quarter, HoldingsChannel.com reports. The institutional investor bought 1,171 shares of the medical research company’s stock, valued at approximately $285,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in TMO. Neville Rodie & Shaw Inc. lifted its position in Thermo Fisher Scientific by 1.7% during the third quarter. Neville Rodie & Shaw Inc. now owns 114,536 shares of the medical research company’s stock valued at $27,956,000 after buying an additional 1,965 shares in the last quarter. CENTRAL TRUST Co lifted its position in Thermo Fisher Scientific by 2.2% during the third quarter. CENTRAL TRUST Co now owns 27,717 shares of the medical research company’s stock valued at $6,765,000 after buying an additional 607 shares in the last quarter. Summit Financial Group Inc. acquired a new position in Thermo Fisher Scientific during the third quarter valued at approximately $201,000. Fulton Bank N.A. lifted its position in Thermo Fisher Scientific by 11.4% during the third quarter. Fulton Bank N.A. now owns 4,040 shares of the medical research company’s stock valued at $986,000 after buying an additional 414 shares in the last quarter. Finally, United Services Automobile Association lifted its position in Thermo Fisher Scientific by 9.4% during the second quarter. United Services Automobile Association now owns 569,361 shares of the medical research company’s stock valued at $117,937,000 after buying an additional 49,152 shares in the last quarter. 85.96% of the stock is currently owned by institutional investors and hedge funds.

In other news, CEO Marc N. Casper sold 50,000 shares of the business’s stock in a transaction on Monday, August 6th. The shares were sold at an average price of $233.95, for a total transaction of $11,697,500.00. Following the transaction, the chief executive officer now directly owns 320,122 shares of the company’s stock, valued at $74,892,541.90. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Marc N. Casper sold 125,520 shares of the business’s stock in a transaction on Monday, October 1st. The stock was sold at an average price of $247.50, for a total transaction of $31,066,200.00. The disclosure for this sale can be found here. Over the last three months, insiders have sold 196,070 shares of company stock worth $47,569,729. Corporate insiders own 0.49% of the company’s stock.

NYSE TMO opened at $231.41 on Friday. Thermo Fisher Scientific Inc. has a 52 week low of $181.51 and a 52 week high of $249.95. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.11 and a current ratio of 1.58. The firm has a market cap of $98.31 billion, a PE ratio of 24.38, a PEG ratio of 1.78 and a beta of 1.12.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, July 25th. The medical research company reported $2.75 EPS for the quarter, topping analysts’ consensus estimates of $2.63 by $0.12. Thermo Fisher Scientific had a net margin of 10.36% and a return on equity of 16.28%. The business had revenue of $6.08 billion for the quarter, compared to analysts’ expectations of $5.90 billion. During the same period in the previous year, the company posted $2.30 earnings per share. The business’s revenue for the quarter was up 21.8% compared to the same quarter last year. As a group, equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 10.98 earnings per share for the current year.

Thermo Fisher Scientific declared that its board has approved a share repurchase program on Friday, September 7th that permits the company to buyback $2.00 billion in outstanding shares. This buyback authorization permits the medical research company to repurchase up to 2.1% of its shares through open market purchases. Shares buyback programs are usually an indication that the company’s management believes its stock is undervalued.

A number of brokerages have weighed in on TMO. Zacks Investment Research raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $261.00 price target on the stock in a research report on Monday, August 6th. Leerink Swann lifted their price target on shares of Thermo Fisher Scientific from $239.00 to $255.00 and gave the company an “outperform” rating in a research report on Thursday, July 26th. ValuEngine raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research report on Tuesday, July 24th. UBS Group began coverage on shares of Thermo Fisher Scientific in a research report on Tuesday. They set a “buy” rating and a $295.00 price target on the stock. Finally, JPMorgan Chase & Co. reaffirmed an “overweight” rating and set a $300.00 price target on shares of Thermo Fisher Scientific in a research report on Thursday, July 26th. One investment analyst has rated the stock with a hold rating and twelve have issued a buy rating to the stock. Thermo Fisher Scientific presently has a consensus rating of “Buy” and an average target price of $259.91.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

Featured Article: Insider Trading

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply